Thermo Fisher Scientific Factor XII Polyclonal Antibody

Applications

Western Blot (WB)

• Tested Dilution: 0.04–0.4 µg/mL

Immunohistochemistry (Paraffin) (IHC (P))

• Tested Dilution: 1:20–1:50

Product Specifications

Product Specific Information

Immunogen sequence:
YHKCTHKGRP GPQPWCATTP NFDQDQRWGY CLEPKKVKDH CSKHSPCQKG GTCVNMPSGP HCLCPQHLTG NHCQKEKCFE PQLLRFFHKN EIWYRTEQAA VARCQCKGPD A

Target Information

This single chain zymogen is converted to a two-chain serine protease with a heavy chain (alpha-factor XIIa) and a light chain.
The heavy chain contains two fibronectin-type domains, two epidermal growth factor (EGF)-like domains, a kringle domain, and a proline-rich domain, whereas the light chain contains only a catalytic domain.
On activation, further cleavages take place in the heavy chain, resulting in the production of beta-factor XIIa light chain and the alpha-factor XIIa light chain becomes beta-factor XIIa heavy chain.
Prekallikrein is cleaved by factor XII to form kallikrein, which then cleaves factor XII first to alpha-factor XIIa and then to beta-factor XIIa.
The active factor XIIa participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. It activates coagulation factors VII and XI.
Defects in this gene do not cause any clinical symptoms and the sole effect is that whole-blood clotting time is prolonged.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.